<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-02-25" updated="2019-12-02">
  <drugbank-id primary="true">DB11386</drugbank-id>
  <name>Chlorobutanol</name>
  <description>Chlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. It also elicits sedative-hypnotic and weak local anesthetic actions in addition to antibacterial and antifungal properties. Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone. &#13;
&#13;
As a long-term stabilizer of multi-ingredient preparations, chlorobutanol is normally used at a concentration of 0.5%. At this concentration, it also conserves its antimicrobial activity. &#13;
&#13;
Due to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743]. Chlorobutanol is a common detergent preservative in eye drops and other ophthalmic therapeutic formulations [A32744].</description>
  <cas-number>57-15-8</cas-number>
  <unii>HM4YQM8WRC</unii>
  <average-mass>177.45</average-mass>
  <monoisotopic-mass>175.9562479</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32739</ref-id>
        <pubmed-id>2096493</pubmed-id>
        <citation>Chen SL, Yang WC, Huang TP, Wann SA, Teng CM: Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro. Thromb Haemost. 1990 Nov 30;64(3):473-7.</citation>
      </article>
      <article>
        <ref-id>A32740</ref-id>
        <pubmed-id>1083146</pubmed-id>
        <citation>Hermsmeyer K, Aprigliano O: Effects of chlorobutanol and bradykinin on myocardial excitation. Am J Physiol. 1976 Feb;230(2):306-10. doi: 10.1152/ajplegacy.1976.230.2.306.</citation>
      </article>
      <article>
        <ref-id>A32743</ref-id>
        <pubmed-id>7159691</pubmed-id>
        <citation>Tung C, Graham GG, Wade DN, Williams KM: The pharmacokinetics of chlorbutol in man. Biopharm Drug Dispos. 1982 Oct-Dec;3(4):371-8.</citation>
      </article>
      <article>
        <ref-id>A32744</ref-id>
        <pubmed-id>19284328</pubmed-id>
        <citation>Epstein SP, Ahdoot M, Marcus E, Asbell PA: Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009 Apr;25(2):113-9. doi: 10.1089/jop.2008.0098.</citation>
      </article>
      <article>
        <ref-id>A32746</ref-id>
        <pubmed-id>11783457</pubmed-id>
        <citation>Noecker R: Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001 Sep-Oct;18(5):205-15.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>No approved therapeutic indications on its own. </indication>
  <pharmacodynamics>Chlorobutanol is a detergent preservative with a broad spectrum of antimicrobial activity [A32744]. _In vitro_, chlorobutanol demonstrated to inhibit platelet aggregation and release via unknown mechanisms [A32739]. A study proposes that the antiplatelet effect of chlorobutanol may occur from inhibition of the arachidonic acid pathway [A32739]. It attenuated thromboxane B2 formation, elevation of cytosolic free calcium, and ATP release, and additionally exhibited a significant inhibitory activity toward several aggregation inducers in a time- and concentration-dependent manner [A32739]. Chlorobutanol may exert a direct negative inotropic effect on myocardial cells to isometric tension produced by the heart [A32740]. Chlorobutanol was shown to induce conjunctival and corneal cell toxicity _in vitro_: at a concentration of 0.1%, Cbl caused near depletion of the squamous layer while degeneration of corneal epithelial cells, generation of conspicuous membranous blebs, cytoplasmic swelling, and occasional breaks in the external cell membrane were observed at a concentration of 0.5% [A32744]. </pharmacodynamics>
  <mechanism-of-action>As a detergent, chlorobutanol disrupts the lipid structure of the cell membrane and increases the cell permeability, leading to cell lysis [A32744]. It induces conjunctival and corneal cell toxicity via causing cell retraction and cessation of normal cytokines, cell movement, and mitotic activity [A32744]. It disrupts the barrier and transport properties of the corneal epithelium as well as inhibits the utilization of oxygen by the cornea [A32744]. Chlorobutanol also inhibits oxygen use by the cornea, which increases susceptibility to infection [A32746].</mechanism-of-action>
  <toxicity>Oral LD50 of anhydrous chlorobutanol in rat is 510 mg/kg [MSDS]. Chlorobutanol was shown to induce conjunctival and corneal cell toxicity _in vitro_</toxicity>
  <metabolism>Chlorobutanol is reported to undergo glucuronidation and sulphation [A32743].</metabolism>
  <absorption>Following oral administration in healthy subjects, the plasma concentration fell by 50% in 24 hours post-administration [A32743].</absorption>
  <half-life>Following oral administration, the terminal elimination half life in healthy subjects was 10.3 ± 1.3 days [A32743]. </half-life>
  <protein-binding>The binding to plasma proteins was 57 ± 3% [A32743]. </protein-binding>
  <route-of-elimination>Under physiological conditions, chlorobutanol is unstable. The mean urinary recovery accounts for 9.6% of the dose orally administered [A32743]. </route-of-elimination>
  <volume-of-distribution>The volume of distribution was approximately 233 ± 141 L in healthy individuals receiving oral chlorobutanol [A32743].</volume-of-distribution>
  <clearance>In healthy subjects, the clearance was approximately 11.6 ± 1.0 mL/min following oral administration [A32743]. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tertiary alcohols. These are compounds in which a hydroxy group, -OH, is attached to a saturated carbon atom R3COH (R not H ).</description>
    <direct-parent>Tertiary alcohols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Alcohols and polyols</subclass>
    <alternative-parent>Alkyl chlorides</alternative-parent>
    <alternative-parent>Chlorohydrins</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alkyl chloride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Chlorohydrin</substituent>
    <substituent>Halohydrin</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Tertiary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Chloretone</synonym>
    <synonym language="english" coder="inn">Chlorobutanol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aurisan Dps</name>
      <labeller>Lab Nadeau LtÉe, Division Of Technilab Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00417009</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-28</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Balminil Nasal Ointment</name>
      <labeller>Rougier Pharma Division Of Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02135639</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2003-09-22</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cerumol</name>
      <labeller>Thornton &amp; Ross Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00221570</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dry Socket Paste</name>
      <labeller>Sultan Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00479225</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-06</ended-marketing-on>
      <dosage-form>Paste</dosage-form>
      <strength/>
      <route>Dental</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gouttes Pour Mal D'oreilles</name>
      <labeller>Lab Valmo EnregistrÉ, Division Of Technilab Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00542865</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-24</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Larynsol Loz</name>
      <labeller>Herbes Universelles Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00444758</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2009-07-15</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neutralite Liq</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00313467</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2012-11-20</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oralgar Dps</name>
      <labeller>Produits Marc O (1987) Inc., Division Of Technilab Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00400602</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-15</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Outgro Liquid</name>
      <labeller>Whitehall Robins Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01934015</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-07</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rhino-vaccin</name>
      <labeller>Rougier Pharma Division Of Ratiopharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00167983</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2009-08-04</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cerumol</name>
      <ingredients>Chlorobutanol + Dichlorobenzene + Peanut oil + Turpentine</ingredients>
    </mixture>
    <mixture>
      <name>Dry Socket Paste</name>
      <ingredients>Acetylsalicylic acid + Chlorobutanol + Eugenol</ingredients>
    </mixture>
    <mixture>
      <name>Balminil Nasal Ointment</name>
      <ingredients>Camphor + Chlorobutanol + Ephedrine + Eucalyptol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Neutralite Liq</name>
      <ingredients>Chlorobutanol + Monopotassium phosphate + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Aurisan Dps</name>
      <ingredients>Benzocaine + Camphor + Chlorobutanol</ingredients>
    </mixture>
    <mixture>
      <name>Oralgar Dps</name>
      <ingredients>Benzocaine + Camphor + Chlorobutanol</ingredients>
    </mixture>
    <mixture>
      <name>Larynsol Loz</name>
      <ingredients>Benzoic acid + Chlorobutanol + Eucalyptol</ingredients>
    </mixture>
    <mixture>
      <name>Gouttes Pour Mal D'oreilles</name>
      <ingredients>Benzocaine + Camphor + Chlorobutanol</ingredients>
    </mixture>
    <mixture>
      <name>Outgro Liquid</name>
      <ingredients>Chlorobutanol + Tannic acid</ingredients>
    </mixture>
    <mixture>
      <name>Rhino-vaccin</name>
      <ingredients>Camphor + Chlorobutanol + Ephedrine + Eucalyptol + Levomenthol</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiemetics and Antinauseants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Butanols</category>
      <mesh-id>D000440</mesh-id>
    </category>
    <category>
      <category>Chlorohydrins</category>
      <mesh-id>D002728</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Fatty Alcohols</category>
      <mesh-id>D005233</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Pharmaceutic Aids</category>
      <mesh-id>D010592</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Preservatives, Pharmaceutical</category>
      <mesh-id>D011310</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Ointment</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Paste</form>
      <route>Dental</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A04AD54">
      <level code="A04AD">Other antiemetics</level>
      <level code="A04A">ANTIEMETICS AND ANTINAUSEANTS</level>
      <level code="A04">ANTIEMETICS AND ANTINAUSEANTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A04AD04">
      <level code="A04AD">Other antiemetics</level>
      <level code="A04A">ANTIEMETICS AND ANTINAUSEANTS</level>
      <level code="A04">ANTIEMETICS AND ANTINAUSEANTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11386.pdf?1524771324</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.31</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.65e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.75</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1,1,1-trichloro-2-methylpropan-2-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>chlorobutanol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>177.45</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>175.9562479</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(C)(O)C(Cl)(Cl)Cl</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C4H7Cl3O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C4H7Cl3O/c1-3(2,8)4(5,6)7/h8H,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OSASVXMJTNOKOY-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>20.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>37.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.75</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>99</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>167</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6995</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>134813</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5977</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827977</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01942</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>13842993</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50417941</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Chlorobutanol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1439973</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000090</id>
      <name>Potassium voltage-gated channel subfamily H member 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A20119</ref-id>
            <pubmed-id>20071423</pubmed-id>
            <citation>Friemel A, Zunkler BJ: Interactions at human ether-a-go-go-related gene channels. Toxicol Sci. 2010 Apr;114(2):346-55. doi: 10.1093/toxsci/kfq011. Epub 2010 Jan 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q12809" source="Swiss-Prot">
        <name>Potassium voltage-gated channel subfamily H member 2</name>
        <general-function>Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization</general-function>
        <specific-function>Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.</specific-function>
        <gene-name>KCNH2</gene-name>
        <locus>7q35-q36</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>404-424
451-471
496-516
521-541
548-568
639-659</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.97</theoretical-pi>
        <molecular-weight>126653.52</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6251</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>KCNH2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U04270</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>487738</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>572</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>572</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q12809</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>KCNH2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Eag homolog</synonym>
          <synonym>Eag-related protein 1</synonym>
          <synonym>ERG</synonym>
          <synonym>ERG-1</synonym>
          <synonym>ERG1</synonym>
          <synonym>Ether-a-go-go-related gene potassium channel 1</synonym>
          <synonym>Ether-a-go-go-related protein 1</synonym>
          <synonym>H-ERG</synonym>
          <synonym>HERG</synonym>
          <synonym>hERG-1</synonym>
          <synonym>hERG1</synonym>
          <synonym>Voltage-gated potassium channel subunit Kv11.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000180|Potassium voltage-gated channel subfamily H member 2
MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVM
QRPCTCDFLHGPRTQRRAAAQIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKNEDG
AVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARESSV
RSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP
PRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPP
RHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIA
PKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIY
TAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANE
EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLD
RYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSS
GLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVS
AIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF
PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALY
FISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLE
VLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRRTDKDTE
QPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSS
PRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTP
SLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSA
VTTPGPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPG
QLGALTSQPLHRHGSDPGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021259|Potassium voltage-gated channel subfamily H member 2 (KCNH2)
ATGCCGGTGCGGAGGGGCCACGTCGCGCCGCAGAACACCTTCCTGGACACCATCATCCGC
AAGTTTGAGGGCCAGAGCCGTAAGTTCATCATCGCCAACGCTCGGGTGGAGAACTGCGCC
GTCATCTACTGCAACGACGGCTTCTGCGAGCTGTGCGGCTACTCGCGGGCCGAGGTGATG
CAGCGACCCTGCACCTGCGACTTCCTGCACGGGCCGCGCACGCAGCGCCGCGCTGCCGCG
CAGATCGCGCAGGCACTGCTGGGCGCCGAGGAGCGCAAAGTGGAAATCGCCTTCTACCGG
AAAGATGGGAGCTGCTTCCTATGTCTGGTGGATGTGGTGCCCGTGAAGAACGAGGATGGG
GCTGTCATCATGTTCATCCTCAATTTCGAGGTGGTGATGGAGAAGGACATGGTGGGGTCC
CCGGCTCATGACACCAACCACCGGGGCCCCCCCACCAGCTGGCTGGCCCCAGGCCGCGCC
AAGACCTTCCGCCTGAAGCTGCCCGCGCTGCTGGCGCTGACGGCCCGGGAGTCGTCGGTG
CGGTCGGGCGGCGCGGGCGGCGCGGGCGCCCCGGGGGCCGTGGTGGTGGACGTGGACCTG
ACGCCCGCGGCACCCAGCAGCGAGTCGCTGGCCCTGGACGAAGTGACAGCCATGGACAAC
CACGTGGCAGGGCTCGGGCCCGCGGAGGAGCGGCGTGCGCTGGTGGGTCCCGGCTCTCCG
CCCCGCAGCGCGCCCGGCCAGCTCCCATCGCCCCGGGCGCACAGCCTCAACCCCGACGCC
TCGGGCTCCAGCTGCAGCCTGGCCCGGACGCGCTCCCGAGAAAGCTGCGCCAGCGTGCGC
CGCGCCTCGTCGGCCGACGACATCGAGGCCATGCGCGCCGGGGTGCTGCCCCCGCCACCG
CGCCACGCCAGCACCGGGGCCATGCACCCACTGCGCAGCGGCTTGCTCAACTCCACCTCG
GACTCCGACCTCGTGCGCTACCGCACCATTAGCAAGATTCCCCAAATCACCCTCAACTTT
GTGGACCTCAAGGGCGACCCCTTCTTGGCTTCGCCCACCAGTGACCGTGAGATCATAGCA
CCTAAGATAAAGGAGCGAACCCACAATGTCACTGAGAAGGTCACCCAGGTCCTGTCCCTG
GGCGCCGACGTGCTGCCTGAGTACAAGCTGCAGGCACCGCGCATCCACCGCTGGACCATC
CTGCATTACAGCCCCTTCAAGGCCGTGTGGGACTGGCTCATCCTGCTGCTGGTCATCTAC
ACGGCTGTCTTCACACCCTACTCGGCTGCCTTCCTGCTGAAGGAGACGGAAGAAGGCCCG
CCTGCTACCGAGTGTGGCTACGCCTGCCAGCCGCTGGCTGTGGTGGACCTCATCGTGGAC
ATCATGTTCATTGTGGACATCCTCATCAACTTCCGCACCACCTACGTCAATGCCAACGAG
GAGGTGGTCAGCCACCCCGGCCGCATCGCCGTCCACTACTTCAAGGGCTGGTTCCTCATC
GACATGGTGGCCGCCATCCCCTTCGACCTGCTCATCTTCGGCTCTGGCTCTGAGGAGCTG
ATCGGGCTGCTGAAGACTGCGCGGCTGCTGCGGCTGGTGCGCGTGGCGCGGAAGCTGGAT
CGCTACTCAGAGTACGGCGCGGCCGTGCTGTTCTTGCTCATGTGCACCTTTGCGCTCATC
GCGCACTGGCTAGCCTGCATCTGGTACGCCATCGGCAACATGGAGCAGCCACACATGGAC
TCACGCATCGGCTGGCTGCACAACCTGGGCGACCAGATAGGCAAACCCTACAACAGCAGC
GGCCTGGGCGGCCCCTCCATCAAGGACAAGTATGTGACGGCGCTCTACTTCACCTTCAGC
AGCCTCACCAGTGTGGGCTTCGGCAACGTCTCTCCCAACACCAACTCAGAGAAGATCTTC
TCCATCTGCGTCATGCTCATTGGCTCCCTCATGTATGCTAGCATCTTCGGCAACGTGTCG
GCCATCATCCAGCGGCTGTACTCGGGCACAGCCCGCTACCACACACAGATGCTGCGGGTG
CGGGAGTTCATCCGCTTCCACCAGATCCCCAATCCCCTGCGCCAGCGCCTCGAGGAGTAC
TTCCAGCACGCCTGGTCCTACACCAACGGCATCGACATGAACGCGGTGCTGAAGGGCTTC
CCTGAGTGCCTGCAGGCTGACATCTGCCTGCACCTGAACCGCTCACTGCTGCAGCACTGC
AAACCCTTCCGAGGGGCCACCAAGGGCTGCCTTCGGGCCCTGGCCATGAAGTTCAAGACC
ACACATGCACCGCCAGGGGACACACTGGTGCATGCTGGGGACCTGCTCACCGCCCTGTAC
TTCATCTCCCGGGGCTCCATCGAGATCCTGCGGGGCGACGTCGTCGTGGCCATCCTGGGG
AAGAATGACATCTTTGGGGAGCCTCTGAACCTGTATGCAAGGCCTGGCAAGTCGAACGGG
GATGTGCGGGCCCTCACCTACTGTGACCTACACAAGATCCATCGGGACGACCTGCTGGAG
GTGCTGGACATGTACCCTGAGTTCTCCGACCACTTCTGGTCCAGCCTGGAGATCACCTTC
AACCTGCGAGATACCAACATGATCCCGGGCTCCCCCGGCAGTACGGAGTTAGAGGGTGGC
TTCAGTCGGCAACGCAAGCGCAAGTTGTCCTTCCGCAGGCGCACGGACAAGGACACGGAG
CAGCCAGGGGAGGTGTCGGCCTTGGGGCCGGGCCGGGCGGGGGCAGGGCCGAGTAGCCGG
GGCCGGCCGGGGGGGCCGTGGGGGGAGAGCCCGTCCAGTGGCCCCTCCAGCCCTGAGAGC
AGTGAGGATGAGGGCCCAGGCCGCAGCTCCAGCCCCCTCCGCCTGGTGCCCTTCTCCAGC
CCCAGGCCCCCCGGAGAGCCGCCGGGTGGGGAGCCCCTGATGGAGGACTGCGAGAAGAGC
AGCGACACTTGCAACCCCCTGTCAGGCGCCTTCTCAGGAGTGTCCAACATTTTCAGCTTC
TGGGGGGACAGTCGGGGCCGCCAGTACCAGGAGCTCCCTCGATGCCCCGCCCCCACCCCC
AGCCTCCTCAACATCCCCCTCTCCAGCCCGGGTCGGCGGCCCCGGGGCGACGTGGAGAGC
AGGCTGGATGCCCTCCAGCGCCAGCTCAACAGGCTGGAGACCCGGCTGAGTGCAGACATG
GCCACTGTCCTGCAGCTGCTACAGAGGCAGATGACGCTGGTCCCGCCCGCCTACAGTGCT
GTGACCACCCCGGGGCCTGGCCCCACTTCCACATCCCCGCTGTTGCCCGTCAGCCCCCTC
CCCACCCTCACCTTGGACTCGCTTTCTCAGGTTTCCCAGTTCATGGCGTGTGAGGAGCTG
CCCCCGGGGGCCCCAGAGCTTCCCCAAGAAGGCCCCACACGACGCCTCTCCCTACCGGGC
CAGCTGGGGGCCCTCACCTCCCAGCCCCTGCACAGACACGGCTCGGACCCGGGCAGTTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF00027</identifier>
            <name>cNMP_binding</name>
          </pfam>
          <pfam>
            <identifier>PF13426</identifier>
            <name>PAS_9</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated potassium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>C3HC4-type RING finger domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>delayed rectifier potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inward rectifier potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphorelay sensor kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane repolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane repolarization during cardiac muscle cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of potassium ion export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion export across plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate by cardiac conduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate by hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ventricular cardiac muscle cell membrane repolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle cell action potential</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>